Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
Invivyd filed a standard 8-K, no major news yet.
AI Summary
Invivyd, Inc. filed an 8-K on September 23, 2024, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not appear to contain specific material events or financial figures beyond standard reporting requirements.
Why It Matters
This 8-K filing indicates Invivyd, Inc. is fulfilling its reporting obligations with the SEC. Investors should review the full filing for any specific disclosures that may impact the company's valuation or operations.
Risk Assessment
Risk Level: low — The filing appears to be a routine 8-K with no immediate material events disclosed, suggesting low immediate risk from this specific filing.
Key Numbers
- 001-40703 — SEC File Number (Identifies the company's filing with the SEC)
- 85-1403134 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former company name
- September 23, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Invivyd, Inc. in this 8-K?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the significance of the former company name 'Adagio Therapeutics, Inc.'?
The filing indicates that Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a name change date of November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the SEC Act under which this 8-K is filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Does this filing disclose any new financial statements or exhibits?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the content of these exhibits is not detailed in the provided text.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-09-23 07:07:14
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20240923.htm (8-K) — 49KB
- ivvd-ex99_1.htm (EX-99.1) — 42KB
- img59752938_0.jpg (GRAPHIC) — 12KB
- img59752938_1.jpg (GRAPHIC) — 730KB
- img59752938_2.jpg (GRAPHIC) — 1555KB
- img59752938_3.jpg (GRAPHIC) — 867KB
- img59752938_4.jpg (GRAPHIC) — 979KB
- img59752938_5.jpg (GRAPHIC) — 1059KB
- img59752938_6.jpg (GRAPHIC) — 1059KB
- img59752938_7.jpg (GRAPHIC) — 841KB
- 0000950170-24-108624.txt ( ) — 10000KB
- ivvd-20240923.xsd (EX-101.SCH) — 31KB
- ivvd-20240923_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On September 23, 2024, Invivyd, Inc. issued a press release entitled "Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart)" A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: September 23, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary